BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30569866)

  • 1. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
    Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
    Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.
    Diab S; Abdelaziz AM; Li P; Teo T; Basnet SKC; Noll B; Rahaman MH; Lu J; Hou J; Yu M; Le BT; Albrecht H; Milne RW; Wang S
    Eur J Med Chem; 2017 Oct; 139():762-772. PubMed ID: 28863357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation.
    Yu M; Li P; Basnet SK; Kumarasiri M; Diab S; Teo T; Albrecht H; Wang S
    Eur J Med Chem; 2015 May; 95():116-26. PubMed ID: 25800647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.
    Teo T; Lam F; Yu M; Yang Y; Basnet SK; Albrecht H; Sykes MJ; Wang S
    Mol Pharmacol; 2015 Aug; 88(2):380-9. PubMed ID: 26044548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
    Teo T; Yang Y; Yu M; Basnet SK; Gillam T; Hou J; Schmid RM; Kumarasiri M; Diab S; Albrecht H; Sykes MJ; Wang S
    Eur J Med Chem; 2015 Oct; 103():539-50. PubMed ID: 26408454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
    Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
    Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
    Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
    Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
    Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
    Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
    Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
    Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine derivatives as Mnk1/2 inhibitors.
    Xing K; Zhang H; Wang S; Li J; Mu Z; Zhang L; Zuo S; Wang Y; Li S; Wu B; Jing Y; Wen J; Liu D; Huang M; Zhao L
    Eur J Med Chem; 2024 Jun; 272():116499. PubMed ID: 38759457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
    Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
    J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
    Wang S; Li B; Liu B; Huang M; Li D; Guan L; Zang J; Liu D; Zhao L
    Bioorg Med Chem; 2018 Sep; 26(16):4602-4614. PubMed ID: 30115493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis and Bioactivity Evaluation of 4,6-Disubstituted Pyrido[3,2-
    Xing K; Zhang J; Han Y; Tong T; Liu D; Zhao L
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32967084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of 4,6-Disubstituted Pyrido[3,2-
    Han Y; Zhang H; Wang S; Li B; Xing K; Shi Y; Cao H; Zhang J; Tong T; Zang J; Guan L; Gao X; Wang Y; Liu D; Huang M; Jing Y; Zhao L
    J Med Chem; 2021 Sep; 64(18):13719-13735. PubMed ID: 34515481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
    Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in developing MNK inhibitors.
    Jin X; Yu R; Wang X; Proud CG; Jiang T
    Eur J Med Chem; 2021 Jul; 219():113420. PubMed ID: 33892273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.
    Kwiatkowski J; Liu B; Pang S; Ahmad NHB; Wang G; Poulsen A; Yang H; Poh YR; Tee DHY; Ong E; Retna P; Dinie N; Kwek P; Wee JLK; Manoharan V; Low CB; Seah PG; Pendharkar V; Sangthongpitag K; Joy J; Baburajendran N; Jansson AE; Nacro K; Hill J; Keller TH; Hung AW
    J Med Chem; 2020 Jan; 63(2):621-637. PubMed ID: 31910010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.
    Abdelaziz AM; Basnet SKC; Islam S; Li M; Tadesse S; Albrecht H; Gerber C; Yu M; Wang S
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2650-2654. PubMed ID: 31362920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.